Impact of a Personalized Medication Plan on Duration of Treatment With Potent Opioids in Acute Non-cancer Musculoskeletal Pain.

Summary

The aim of this study is to evaluate whether patients who benefit from a personalized pharmaceutical plan (PPP) during their hospitalization, allowing them to be informed and sensitized, are treated for a shorter period of time with strong opioids with a reduced risk of dependence compared to a management according to the usual modalities in the rheumatology services concerned.

Eligibility

Inclusion Criteria:

* Patient hospitalized in the rheumatology department
* Patient with acute pain in the context of a non-cancerous, non-traumatic, high-energy musculoskeletal pathology
* Patient for whom a prescription of strong opioid derivatives is initiated in rheumatology or patient for whom a prescription of strong opioid derivatives is maintained in rheumatology if the initial prescription has a maximum duration of 30 consecutive days prior to inclusion

Exclusion Criteria:

* Patient with cancer or fibromyalgia already diagnosed at inclusion
* Patient with poor French language skills
* Taking a strong opioid treatment for more than 30 consecutive days prior to inclusion
* Person judged by the prescriber or pharmacist as not autonomous for the management of strong opioid treatment
* Patient already included in the study

Conditions2

Browse More Trials